Protalix BioTherapeutics, Inc. (PLX)
- Previous Close
1.1400 - Open
1.1400 - Bid --
- Ask --
- Day's Range
1.1300 - 1.2000 - 52 Week Range
1.0300 - 2.5100 - Volume
388,901 - Avg. Volume
425,593 - Market Cap (intraday)
87.979M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
15.00 - EPS (TTM)
0.0800 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
www.protalix.comRecent News: PLX
Performance Overview: PLX
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLX
Valuation Measures
Market Cap
87.98M
Enterprise Value
65.86M
Trailing P/E
15.00
Forward P/E
10.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.74
Price/Book (mrq)
2.95
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
6.03
Financial Highlights
Profitability and Income Statement
Profit Margin
11.48%
Return on Assets (ttm)
6.45%
Return on Equity (ttm)
44.48%
Revenue (ttm)
59.65M
Net Income Avi to Common (ttm)
6.85M
Diluted EPS (ttm)
0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
48.49M
Total Debt/Equity (mrq)
88.54%
Levered Free Cash Flow (ttm)
5.05M
Research Analysis: PLX
Company Insights: PLX
PLX does not have Company Insights